Novo Holdings reports Total Income and Investment Returns of DKK 31 billion (€4.2 billion) for 2023. Total Assets grow by 38% to DKK 1,114 billion (€149 billion) : vimarsana.com

Novo Holdings reports Total Income and Investment Returns of DKK 31 billion (€4.2 billion) for 2023. Total Assets grow by 38% to DKK 1,114 billion (€149 billion)

/PRNewswire/ -- Novo Holdings today announced its financial results for 2023*. Strong Investment Portfolio performance, and growth of the Novo Group companies...

Related Keywords

Denmark , United States , Copenhagen , Køavn , Wuxi , Jiangsu , China , Singapore , Hong Kong , America , Danish , Limmatech Biologics , Kasim Kutay , Hillstar Bio , Novo Nordisk , Oxford Biomedica , Acesion Pharma , Terremoto Biosciences , Contract Development , Pureos Bioventures Fund , Impact Fund , Novo Holding , Novo Holdings , Novo Group , Scion Fundi Venture Investments , Novo Group Companies , Biogeneration Capital Fund , Novo Nordisk Foundation , Value Of The Holding , Novo Holdings Investment Portfolio , Manufacturing Organisation , Paratek Pharmaceuticals , Octave Health , Strong Investment Portfolio , Total Income , Investment Returns , Investment Portfolio , Total Investment Return , Total Assets , Life Science Investments , Seed Investments , Venture Investments , Bioindustrial Investments , Asia Investments , Growth Investments , Principal Investments , Capital Investments , Glentra Capital , Special Investments , Alentis Therapeutics , Lexeo Therapeutics , Manat Bio , Maplight Therapeutics , Ray Therapeutics , Scion Fund , Hemab Therapeutics , Seed Investment , Gurnet Point , Deep Branch , Lepure Biotech , Total Investment , Total Value , Total Holdings , Investment Assets , Internal Rate , Time Weighted Returns ,